Influence of High-Dose Highly Efficient Statins on Short-Term Mortality in Patients Undergoing Percutaneous Coronary Intervention With Stenting for Acute Coronary Syndromes

Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention

“…The results showed that eight patients (0.9%) receiving high intensity statin therapy and 21 patients (3.5%) on low intensity statin or no statin at all died during the 3 month follow-up (hazard ratio [HR] 0.244, p ¼ 0.001); after propensity score adjustment the results remained significant 1 . Thus, for 'real-world' patients undergoing PCI for ACS, a significant reduction in short-term all-cause mortality was observed in patients receiving high-intensity statin treatment compared with those on low-intensity treatment or no statins 1 . This beneficial effect of statins was confirmed by a meta-analysis that included 8750 patients from 20 randomized controlled trials (RCTs) 2 .…”

“…From the 1528 patients, 926 (60.6%) received high-dose atorvastatin or rosuvastatin (high intensity) and 602 patients (39.4%) received low-dose statin therapy (low intensity) or were not on a statin at discharge 1 . The results showed that eight patients (0.9%) receiving high intensity statin therapy and 21 patients (3.5%) on low intensity statin or no statin at all died during the 3 month follow-up (hazard ratio [HR] 0.244, p ¼ 0.001); after propensity score adjustment the results remained significant 1 . Thus, for 'real-world' patients undergoing PCI for ACS, a significant reduction in short-term all-cause mortality was observed in patients receiving high-intensity statin treatment compared with those on low-intensity treatment or no statins 1 .…”

“…A recent 'real world' single center study presented data on the progression of cardiovascular disease (CVD) after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) in relation to the level of intensity of statin use prior to PCI 1 . This prospective study included 1528 consecutive patients undergoing PCI during an 8 year period; the primary endpoint was all-cause mortality 1 .…”

“…This prospective study included 1528 consecutive patients undergoing PCI during an 8 year period; the primary endpoint was all-cause mortality 1 . From the 1528 patients, 926 (60.6%) received high-dose atorvastatin or rosuvastatin (high intensity) and 602 patients (39.4%) received low-dose statin therapy (low intensity) or were not on a statin at discharge 1 .…”

“…This prospective study included 1528 consecutive patients undergoing PCI during an 8 year period; the primary endpoint was all-cause mortality 1 . From the 1528 patients, 926 (60.6%) received high-dose atorvastatin or rosuvastatin (high intensity) and 602 patients (39.4%) received low-dose statin therapy (low intensity) or were not on a statin at discharge 1 . The results showed that eight patients (0.9%) receiving high intensity statin therapy and 21 patients (3.5%) on low intensity statin or no statin at all died during the 3 month follow-up (hazard ratio [HR] 0.244, p ¼ 0.001); after propensity score adjustment the results remained significant 1 .…”